FDA Approves Second Imaging Agent in Less Than 6 Months
Just under six months ago, the FDA approved the first radiopharmaceutical, Gallium-68 PSMA-11, for prostate cancer (PCa) detection by PET-CT scans. Approval meant that this injectable isotope had achieved special status as “a first”. The FDA granted its approval for two purposes: (a) Suspicion of PCa recurrence after treatment, and (b)Suspicion of metastasis (spread) at keep reading